COLUMBIA, Md.--(BUSINESS WIRE)--CELSION CORPORATION (NASDAQ: CLN) announced today that X-ray (CT) images of liver lesions from its Phase I liver cancer study of ThermoDox in combination with RadioFrequency Ablation treating patients with primary and metastatic liver cancer were presented in an oral paper at the Society for Interventional Radiology 33rd annual scientific meeting in Washington DC. The presentation, entitled “Imaging Features in Patients undergoing Liver RFA plus Heat Deployed Nanoparticles” was delivered by Julia Locklin. The presented images showed differences in the X-ray appearance and size of tumors following treatment with ThermoDox in combination with RadioFrequency Ablation when compared to tumors of other patients treated with RadioFrequency Ablation alone. While this very preliminary finding is promising, these differences will be further assessed in the Company’s planned Phase III randomized study comparing Radiofrequency Ablation with Thermodox to Radiofrequency Ablation alone. The Phase III study anticipates imminent enrollment of its first patient.
